Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Next Previous
Trial Profile

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab; Nivolumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms CaboCHECK

Most Recent Events

  • 21 Dec 2022 Status changed from recruiting to discontinued due to Due to insufficient recruitment rate.
  • 19 Feb 2022 Final analysis (cut off 8-oct -21; n=56) assessing safety and effectiveness of cabozantinib after failure of IO-based therapies presented at the 2022 Genitourinary Cancers Symposium
  • 11 Feb 2021 Planned End Date changed from 8 Mar 2020 to 31 May 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top